Spondylolisthesis Clinical Trials

Find Spondylolisthesis Clinical Trials Near You

Comparison of Radiographic Fusion Rate and Clinical Outcome of Anterior Lumbar and Extreme Lateral Interbody Fusion Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen® Cellular Bone Matrix, a Prospective Randomised Assessor Blind, Monocentric Trial

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The aim of this study is to prospectively investigate the potential for bony fusion of ViviGen® bone graft substitute in comparison to rhBMP-2 in monosegmental ALIF procedure L5/S1 and in monosegmental XLIF procedure L4/5

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

⁃ Patients who have an indication for a monosegmental ALIF procedure on the L5/S1 segment or a monosegmental XLIF procedure on L4/5 (both ALIF and XLIF procedure with or without an additional pedicular stabilisation), e.g., treating conditions such as spondylosis, spondylolisthesis and degenerative disc disorders with back and/or leg pain

• Patients must be 18 - 70 years of age

• Patients must have understood and signed the study information and the informed consent form

• Patients are willing and able to complete scheduled follow-up evaluations / questionnaires as described in the Informed Consent

Locations
Other Locations
Switzerland
Orthopädie Sonnenhof
RECRUITING
Bern
Contact Information
Primary
Diel Peter, Dr. med
peter.diel@sonnenhof.ch
+41 31 358 17 90
Backup
Katia Schiegg
Time Frame
Start Date: 2022-10-27
Estimated Completion Date: 2032-12
Participants
Target number of participants: 168
Treatments
Active_comparator: Intervention group 5-5.4 cc ViviGen®
Biological: 5-5.4 cc ViviGen® The ALIF or XLIF fusion patients assigned to this group will receive 5-5.4 cc ViviGen®
Active_comparator: Control group 4-6mg rhBMP-2
Biological: 4-6mg rhBMP-2 The ALIF or XLIF fusion patients assigned to this group will receive 4-6mg rhBMP-2
Sponsors
Leads: Lindenhofgruppe AG

This content was sourced from clinicaltrials.gov